Omda (OMDA) Hisse Özeti
Omda AS, Norveç, İsveç, Danimarka, Finlandiya ve uluslararası alanda sağlık sektörü için yazılım çözümleri sunmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 5/6 |
| Gelecekteki Büyüme | 5/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 1/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
OMDA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Omda AS Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | NOK 36.30 |
| 52 Haftanın En Yüksek Seviyesi | NOK 56.60 |
| 52 Haftanın En Düşük Seviyesi | NOK 33.00 |
| Beta | 0.42 |
| 1 Aylık Değişim | -4.47% |
| 3 Aylık Değişim | -13.57% |
| 1 Yıllık Değişim | -27.98% |
| 3 Yıllık Değişim | -19.69% |
| 5 Yıllık Değişim | -60.54% |
| Halka arzdan bu yana değişim | -56.27% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jun 02
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Shape Future Upside Potential
Narrative Update on Omda The updated analyst price target for Omda shifts from a fair value of NOK57.00 to NOK50.00 as analysts factor in a higher discount rate, more cautious revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple. Analyst Commentary Recent Street research on Omda highlights a mix of optimism about growth and execution, paired with more cautious valuation assumptions and price target resets.Analiz Makalesi • May 23
Omda AS (OB:OMDA) Just Reported, And Analysts Assigned A kr50.00 Price Target
Last week, you might have seen that Omda AS ( OB:OMDA ) released its quarterly result to the market. The early response...Anlatı Güncellemesi • May 10
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Drive Future Upside Potential
Analysts now place Omda's fair value at NOK 57.0, with the updated price target shaped by refreshed discount rate assumptions and recent mixed but generally constructive research commentary on guidance, growth drivers and valuation in the sector. Analyst Commentary Recent research on Omda reflects an active debate on how to balance strong reported execution with more cautious valuation and guidance assumptions.Recent updates
Anlatı Güncellemesi • Jun 02
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Shape Future Upside Potential
Narrative Update on Omda The updated analyst price target for Omda shifts from a fair value of NOK57.00 to NOK50.00 as analysts factor in a higher discount rate, more cautious revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple. Analyst Commentary Recent Street research on Omda highlights a mix of optimism about growth and execution, paired with more cautious valuation assumptions and price target resets.Analiz Makalesi • May 23
Omda AS (OB:OMDA) Just Reported, And Analysts Assigned A kr50.00 Price Target
Last week, you might have seen that Omda AS ( OB:OMDA ) released its quarterly result to the market. The early response...Anlatı Güncellemesi • May 10
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Drive Future Upside Potential
Analysts now place Omda's fair value at NOK 57.0, with the updated price target shaped by refreshed discount rate assumptions and recent mixed but generally constructive research commentary on guidance, growth drivers and valuation in the sector. Analyst Commentary Recent research on Omda reflects an active debate on how to balance strong reported execution with more cautious valuation and guidance assumptions.Anlatı Güncellemesi • Apr 20
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Support Upside Potential
Analysts have adjusted their Omda price target to NOK57.0, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions after recent research highlighted both reduced targets across several firms and continued confidence in Omda's growth runway and program momentum. Analyst Commentary Street research around Omda presents a mix of recalibrated price targets and continued confidence in the company’s ability to execute on its program pipeline.Anlatı Güncellemesi • Apr 06
OMDA: Q4 Outperformance And 2026 Guidance Conservatism Are Expected To Drive Upside
The updated analyst price target for Omda now reflects a more cautious tone seen across recent NOK-based targets, as analysts factor in refreshed models following Q4 results, revised guidance and ongoing debate around how conservative the medium-term outlook might be. Analyst Commentary Street research on Omda clusters around lowered price targets in the near term, but most firms are maintaining positive or neutral ratings, pointing to a mix of execution momentum and valuation questions.Anlatı Güncellemesi • Mar 23
OMDA: Multi Condition Momentum And 2026 Guidance Are Expected To Drive Upside
Analysts have trimmed the Omda fair value estimate from NOK 59 to NOK 57, reflecting updated price targets and modeling that factors in revised profit margin expectations, alongside supportive views on revenue growth and the broader program momentum flagged in recent research notes. Analyst Commentary Recent Street research on Omda points to a reset in expectations around valuation, while still highlighting execution on growth initiatives and Q4 performance.Anlatı Güncellemesi • Mar 08
OMDA: Multi Condition Momentum And 2026 Guidance Are Expected To Unlock Upside
Analysts have nudged our Omda price target slightly lower to NOK 59.0, reflecting modestly higher discount rate and P/E assumptions while still citing solid Q4 execution, program momentum and a generally supportive tone across recent research updates. Analyst Commentary Recent research paints a mixed but generally constructive picture around Omda, with most firms trimming price targets while still pointing to solid execution and program traction after Q4.Anlatı Güncellemesi • Feb 22
OMDA: Cardiometabolic Partnerships And Reduced Multiple Are Expected To Unlock Upside
Analysts have trimmed their Omda price targets by about NOK 3, reflecting slightly higher discount rate assumptions and a lower future P/E multiple, as they balance growth expectations with recent stock performance and client concentration risks. Analyst Commentary Recent Street research on Omda highlights a mix of optimism around the core business and caution around how that story translates into valuation and execution risk.Anlatı Güncellemesi • Feb 07
OMDA: Cardiometabolic Program Expansion And AI Platform Investment Will Drive Future Upside
Analysts have trimmed their average price targets on Omda by a few dollars, reflecting a slightly higher discount rate and a modestly higher assumed future P/E, while still pointing to a mix of growth opportunities in cardiometabolic programs and client concentration risks. Analyst Commentary Recent research on Omda reflects a mix of optimism around long term growth potential and caution around execution and concentration risks.Anlatı Güncellemesi • Jan 24
OMDA: GLP-1 Companion Expansion And AI Investment Will Drive Future Upside
Analysts have trimmed their blended price target for Omda by a few dollars to align with recent cuts and initiations around the $17 to $32 range, citing a combination of strong GLP-1 related momentum, partnership tailwinds, revenue growth potential, and concerns about client concentration and ownership complexity. Analyst Commentary Recent research on Omda reflects a mix of optimism around growth drivers and caution around concentration risks and ownership structure, which together help frame how analysts think about valuation and execution risk.Anlatı Güncellemesi • Jan 10
OMDA: Cardiometabolic Platform Expansion And AI Execution Will Support Future Upside Potential
Analysts have slightly adjusted their outlook on Omda, with a modest change in the implied fair value and Street price targets. This reflects updated views on discount rates, long term growth drivers, and mixed recent research that includes lower targets from Goldman Sachs and Wells Fargo, alongside more constructive targets from BMO Capital and Morgan Stanley.Anlatı Güncellemesi • Dec 22
OMDA: Expanded GLP-1 Programs And AI Offerings Will Drive Future Margin Upside
Analysts have raised their price target on Omda to $59.00, supported by expectations for sustained revenue growth above 20%, expanding margins, and accelerating adoption of its enhanced GLP-1 programs and AI driven offerings. Analyst Commentary Recent Street research reflects a predominantly constructive stance on Omda, with bullish analysts highlighting a combination of strong execution, favorable unit economics, and a long runway for growth as key drivers of upside to the newly raised price target.Anlatı Güncellemesi • Dec 08
OMDA: GLP 1 Program Expansion Will Drive Future Margin Upside
Analysts have raised their price target on Omda to $59.00 per share from a previously implied lower level, citing expectations for sustained 20% plus revenue growth, expanding margins, and accelerating GLP 1 related momentum as key drivers of upside. Analyst Commentary Recent Street commentary highlights a constructive backdrop for Omda, with bullish analysts pointing to a long runway for growth supported by a large, under-penetrated market, strong execution, and accelerating GLP 1 related initiatives.Anlatı Güncellemesi • Nov 24
OMDA: Expanding Market And AI Integration Will Drive Continued Growth Momentum
Analysts have significantly raised Omda's fair value estimate from $35 to $59. They cite strong revenue growth, improved profit margins, an expanding addressable market, and increased momentum in new product rollouts and profitability.Analiz Makalesi • Oct 10
Returns On Capital Are Showing Encouraging Signs At Omda (OB:OMDA)
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Anlatı Güncellemesi • Aug 23
M&A And Competition Will Shape Risk And Opportunity In Healthcare
Despite Omada’s stronger-than-expected growth in members and revenue, robust gross margin gains, and improving clinical partnerships, analysts have lowered the price target from NOK44.00 to NOK35.00 due to a more cautious broader outlook. Analyst Commentary Bullish analysts highlight Omada’s member and revenue growth significantly surpassing expectations, with first-quarter figures beating estimates by 6.7% and 11.5%, respectively.Analiz Makalesi • May 23
Omda AS (OB:OMDA) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, Omda AS ( OB:OMDA ) shares have been powering on, with a gain of 32% in the last thirty...Analiz Makalesi • May 16
These 4 Measures Indicate That Omda (OB:OMDA) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Yeni Anlatı • May 08
Restructuring, Acquisitions And AI Integration Will Secure Operational Efficiency
Restructuring completion and an enhanced acquisition strategy are expected to boost operational efficiency, revenue growth, and earnings.Analiz Makalesi • Apr 08
Little Excitement Around Omda AS' (OB:OMDA) Revenues
Omda AS' ( OB:OMDA ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a buy right now compared to the...Analiz Makalesi • Jan 26
Omda (OB:OMDA) Has A Somewhat Strained Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Dec 21
The Market Doesn't Like What It Sees From Omda AS' (OB:OMDA) Revenues Yet
Omda AS' ( OB:OMDA ) price-to-sales (or "P/S") ratio of 1.5x might make it look like a buy right now compared to the...Analiz Makalesi • Nov 13
Returns On Capital Are Showing Encouraging Signs At Omda (OB:OMDA)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...Analiz Makalesi • Jul 24
Returns At Omda (OB:OMDA) Are On The Way Up
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Typically, we'll want to notice a...Analiz Makalesi • May 22
Omda's (OB:OMDA) Earnings Are Weaker Than They Seem
Despite posting some strong earnings, the market for Omda AS' ( OB:OMDA ) stock hasn't moved much. Our analysis...Analiz Makalesi • Mar 24
Improved Revenues Required Before Omda AS (OB:OMDA) Stock's 28% Jump Looks Justified
Omda AS ( OB:OMDA ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last month...Analiz Makalesi • Jan 24
Fewer Investors Than Expected Jumping On Omda AS (OB:OMDA)
When close to half the companies operating in the Healthcare Services industry in Norway have price-to-sales ratios (or...Analiz Makalesi • Nov 18
Omda's (OB:OMDA) Earnings May Just Be The Starting Point
Omda AS ( OB:OMDA ) recently posted some strong earnings, and the market responded positively. We have done some...Analiz Makalesi • Jun 17
Are Investors Undervaluing CSAM Health Group AS (OB:CSAM) By 44%?
Key Insights The projected fair value for CSAM Health Group is kr81.03 based on 2 Stage Free Cash Flow to Equity CSAM...Hissedar Getirileri
| OMDA | NO Healthcare Services | NO Pazar | |
|---|---|---|---|
| 7D | 2.8% | -0.2% | -0.1% |
| 1Y | -28.0% | -7.9% | 14.1% |
Getiri vs. Endüstri: OMDA geçen yıl % -7.9 oranında getiri sağlayan Norwegian Healthcare Services sektörünün gerisinde kaldı.
Getiri vs Piyasa: OMDA geçen yıl % 14.1 oranında getiri sağlayan Norwegian Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| OMDA volatility | |
|---|---|
| OMDA Average Weekly Movement | 6.8% |
| Healthcare Services Industry Average Movement | 5.9% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in NO Market | 11.1% |
| 10% least volatile stocks in NO Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: OMDA son 3 ayda Norwegian piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: OMDA 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1999 | 256 | Sverre Flatby | omda.com |
Omda AS, Norveç, İsveç, Danimarka, Finlandiya'da ve uluslararası alanda sağlık sektörü için yazılım çözümleri sunmaktadır. Kan, hücre ve doku yönetim sistemi Omda ProSang'dan oluşan laboratuvar bilgi yönetim sistemleri ve onkoloji tedavi yönetim çözümü Omda Cytodose'dan oluşan tıbbi ilaç çözümü sunmaktadır. Şirket ayrıca, EKG ve teşhis depolama aracı Omda Cardio; tıbbi görüntüleme mobil uygulaması Omda CIMA; web tabanlı tıbbi görüntüleme çözümü Omda Media; görüntü yönetimi ve iş akışı Omda Medimaker; görüntü yönetimi çözümü Omda Picsara; entegre bir teleradyoloji sistemi Omda Arcidis; hasta veri aktarım aracı Omda Helsemail; denetim ve iş akışı izleme platformu Omda Plutus; güvenli bir e-bakım iletişim platformu Omda S7 ve hasta veri depolama ve yönetim çözümü Omda XDS dahil olmak üzere bağlantılı sağlık çözümleri sunmaktadır.
Omda AS Temel Bilgiler Özeti
| OMDA temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | NOK 744.43m |
| Kazançlar(TTM) | -NOK 35.92m |
| Gelir(TTM) | NOK 493.60m |
1.5x
P/S Oranı-20.7x
F/K OranıOMDA aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| OMDA gelir tablosu (TTM) | |
|---|---|
| Gelir | NOK 493.60m |
| Gelir Maliyeti | NOK 258.75m |
| Brüt Kâr | NOK 234.85m |
| Diğer Giderler | NOK 270.77m |
| Kazançlar | -NOK 35.92m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
Aug 27, 2026
| Hisse başına kazanç (EPS) | -1.75 |
| Brüt Marj | 47.58% |
| Net Kâr Marjı | -7.28% |
| Borç/Özkaynak Oranı | -2,394.2% |
OMDA uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
1.3%
Mevcut Temettü Verimi-27%
Ödeme OranıŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/15 05:35 |
| Gün Sonu Hisse Fiyatı | 2026/06/12 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Omda AS 3 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Kristian Støle | Carnegie Investment Bank AB |
| Emilie Engen | DNB Carnegie |
| Eirik Rafdal | DNB Carnegie |